Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict

[11] Pawin H(2010)Optimizing topical therapies for treating psoriasis: a consensus conference Cutis 86 5-31

[12] Menter A(2004)Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle Drug Dev Ind Pharm 30 1095-1102

[13] Korman NJ(2008)Emollients, moisturizers, and keratolytic agents in psoriasis Clin Dermatol 26 380-386

[14] Elmets CA(2011)Maximizing patient adherence for optimal outcomes in psoriasis J Eur Acad Dermatol Venereol 25 9-14

[15] Thorneloe RJ(2015)An applicator delivery system for fixed-combination calcipotriene plus betamethasone dipropionate topical suspension (gel): innovating psoriasis vulgaris treatment through patient collaboration Dermatol Ther (Heidelb) 5 235-246

[16] Bundy C(2014)Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis Cutis 94 46-53

[17] Griffiths CE(2002)Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference Cutis 70 327-332

[18] Storm A(2009)The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases Arch Dermatol Res 301 561-571

[19] Andersen SE(2011)Dimensions of patient needs in dermatology: subscales of the patient benefit index Arch Dermatol Res 303 11-17

[20] Benfeldt E(2014)Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP) Arch Dermatol Res 306 667-676

[11] Pawin H(2010)Optimizing topical therapies for treating psoriasis: a consensus conference Cutis 86 5-31

[12] Menter A(2004)Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle Drug Dev Ind Pharm 30 1095-1102

[13] Korman NJ(2008)Emollients, moisturizers, and keratolytic agents in psoriasis Clin Dermatol 26 380-386

[14] Elmets CA(2011)Maximizing patient adherence for optimal outcomes in psoriasis J Eur Acad Dermatol Venereol 25 9-14

[15] Thorneloe RJ(2015)An applicator delivery system for fixed-combination calcipotriene plus betamethasone dipropionate topical suspension (gel): innovating psoriasis vulgaris treatment through patient collaboration Dermatol Ther (Heidelb) 5 235-246

[16] Bundy C(2014)Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis Cutis 94 46-53

[17] Griffiths CE(2002)Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference Cutis 70 327-332

[18] Storm A(2009)The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases Arch Dermatol Res 301 561-571

[19] Andersen SE(2011)Dimensions of patient needs in dermatology: subscales of the patient benefit index Arch Dermatol Res 303 11-17

[20] Benfeldt E(2014)Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP) Arch Dermatol Res 306 667-676